Liu Mingjian, Yu Yuyu, Zhang Ziqian, Chen Zhenghong, Chen Bin, Cheng Yijun, Wei Yongxu, Li Jia, Shang Hanbing
Department of Neurosurgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Department of Neurosurgery, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Ann Transl Med. 2021 Nov;9(22):1657. doi: 10.21037/atm-21-5183.
Adipocyte enhancer binding protein 1 (AEBP1) has been shown to be closely related to cancer progression; however research on its potential role in glioblastoma (GBM) remains limited.
Following an expression analysis of AEBP1 in GBM through the Oncomine database, other critical findings were accessed via The Cancer Genome Atlas (TCGA) and Genotype Tissue Expression (GTEx) databases. Specifically, in addition to identifying differentially expressed genes, the Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) were further investigated. Additionally, a gene set enrichment analysis (GSEA) was performed to examine the enrichment pathways in the AEBP1 high-expression group. To examine the prognostic role of AEBP1 in GBM, survival information was obtained from the Chinese Glioma Genome Atlas (CGGA) database. Finally, the relationship between the expression of AEBP1 and immune infiltration in GBM was examined by using the "Gene Module", "Survival Module", and "SCNA Module" on the website "Tumor Immune Estimation Resource (TIMER)".
The Oncomine database revealed that AEBP1 was highly expressed in GBM. The prognostic analyses of 4 independent databases (i.e., TCGA, GTEx, Oncomine, and CGGA) revealed that AEBP1 was an independent predictable marker of GBM. The results of the GSEA showed that protein export, prion disease, cytokine receptor interaction, hematopoietic cell lineage, cell adhesion molecules, apoptosis, and the complement and coagulation cascades were differentially enriched in highly expressed AEBP1 phenotypes. Hence the conclusion is that the high expression of AEBP1 is closely correlated to poor prognosis of GBM. The immune analysis demonstrated that AEBP1 copy number alteration might affect immune infiltration in GBM tissues, and thus the survival outcomes of GBM patients.
High AEBP1 expression in GBM is closely correlated to patient prognosis. AEBP1 is a potential therapeutic target for the inhibition of cancerous progression and the development of new immunotherapies for GBM.
脂肪细胞增强子结合蛋白1（AEBP1）已被证明与癌症进展密切相关；然而，关于其在胶质母细胞瘤（GBM）中的潜在作用的研究仍然有限。
通过Oncomine数据库对GBM中AEBP1进行表达分析后，通过癌症基因组图谱（TCGA）和基因型组织表达（GTEx）数据库获取其他关键发现。具体而言，除了鉴定差异表达基因外，还进一步研究了基因本体论和京都基因与基因组百科全书（KEGG）。此外，进行了基因集富集分析（GSEA）以检查AEBP1高表达组中的富集途径。为了研究AEBP1在GBM中的预后作用，从中国胶质瘤基因组图谱（CGGA）数据库中获取生存信息。最后，通过在“肿瘤免疫评估资源（TIMER）”网站上使用“基因模块”、“生存模块”和“SCNA模块”来研究GBM中AEBP1表达与免疫浸润之间的关系。
Oncomine数据库显示AEBP1在GBM中高表达。对4个独立数据库（即TCGA、GTEx、Oncomine和CGGA）的预后分析表明，AEBP1是GBM的独立预测标志物。GSEA结果显示，蛋白质输出、朊病毒病、细胞因子受体相互作用、造血细胞谱系、细胞粘附分子、细胞凋亡以及补体和凝血级联反应在高表达AEBP1的表型中差异富集。因此得出结论，AEBP1的高表达与GBM的不良预后密切相关。免疫分析表明，AEBP1拷贝数改变可能影响GBM组织中的免疫浸润，进而影响GBM患者的生存结果。
GBM中AEBP1的高表达与患者预后密切相关。AEBP1是抑制癌症进展和开发GBM新免疫疗法的潜在治疗靶点。
